Lyell Immunopharma Statistics
Total Valuation
LYEL has a market cap or net worth of $397.70 million. The enterprise value is -$73.72 million.
| Market Cap | 397.70M |
| Enterprise Value | -73.72M |
Important Dates
The next estimated earnings date is Tuesday, August 6, 2024, after market close.
| Earnings Date | Aug 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
LYEL has 254.94 million shares outstanding. The number of shares has increased by 1.87% in one year.
| Shares Outstanding | 254.94M |
| Shares Change (YoY) | +1.87% |
| Shares Change (QoQ) | +0.57% |
| Owned by Insiders (%) | 15.40% |
| Owned by Institutions (%) | 67.24% |
| Float | 164.22M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5,848.60 |
| Forward PS | n/a |
| PB Ratio | 0.66 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 16.51, with a Debt / Equity ratio of 0.09.
| Current Ratio | 16.51 |
| Quick Ratio | n/a |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -33.90% and return on invested capital (ROIC) is -36.46%.
| Return on Equity (ROE) | -33.90% |
| Return on Assets (ROA) | -29.70% |
| Return on Capital (ROIC) | -36.46% |
| Revenue Per Employee | $304 |
| Profits Per Employee | -$1.02M |
| Employee Count | 224 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -53.43% in the last 52 weeks. The beta is -0.53, so LYEL's price volatility has been lower than the market average.
| Beta (5Y) | -0.53 |
| 52-Week Price Change | -53.43% |
| 50-Day Moving Average | 2.19 |
| 200-Day Moving Average | 2.08 |
| Relative Strength Index (RSI) | 39.40 |
| Average Volume (20 Days) | 1,618,794 |
Short Selling Information
The latest short interest is 17.92 million, so 7.03% of the outstanding shares have been sold short.
| Short Interest | 17.92M |
| Short Previous Month | 24.15M |
| Short % of Shares Out | 7.03% |
| Short % of Float | 10.91% |
| Short Ratio (days to cover) | 12.51 |
Income Statement
In the last 12 months, LYEL had revenue of $68,000 and -$228.34 million in losses. Loss per share was -$0.90.
| Revenue | 68,000 |
| Gross Profit | 68,000 |
| Operating Income | -240.03M |
| Pretax Income | -228.34M |
| Net Income | -228.34M |
| EBITDA | -208.09M |
| EBIT | -228.34M |
| Loss Per Share | -$0.90 |
Balance Sheet
The company has $526.59 million in cash and $55.16 million in debt, giving a net cash position of $471.43 million or $1.85 per share.
| Cash & Cash Equivalents | 526.59M |
| Total Debt | 55.16M |
| Net Cash | 471.43M |
| Net Cash Per Share | $1.85 |
| Equity (Book Value) | 603.16M |
| Book Value Per Share | 2.37 |
| Working Capital | 501.81M |
Cash Flow
In the last 12 months, operating cash flow was -$159.50 million and capital expenditures -$1.18 million, giving a free cash flow of -$160.68 million.
| Operating Cash Flow | -159.50M |
| Capital Expenditures | -1.18M |
| Free Cash Flow | -160.68M |
| FCF Per Share | -$0.63 |
Margins
Gross margin is 100.00%, with operating and profit margins of -352,980.88% and -335,794.12%.
| Gross Margin | 100.00% |
| Operating Margin | -352,980.88% |
| Pretax Margin | -335,794.12% |
| Profit Margin | -335,794.12% |
| EBITDA Margin | -306,019.12% |
| EBIT Margin | -335,794.12% |
| FCF Margin | -236,295.59% |
Dividends & Yields
LYEL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.87% |
| Shareholder Yield | -1.87% |
| Earnings Yield | -57.41% |
| FCF Yield | -40.40% |
Analyst Forecast
The average price target for LYEL is $4.00, which is 156.41% higher than the current price. The consensus rating is "Buy".
| Price Target | $4.00 |
| Price Target Difference | 156.41% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
LYEL has an Altman Z-Score of 0.26 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.26 |
| Piotroski F-Score | 2 |